Patricia Ramírez de la Piscina
A5051384114- Inflammatory Bowel Disease
- Microscopic Colitis
- Pancreatitis Pathology and Treatment
- Diagnosis and treatment of tuberculosis
- Autoimmune and Inflammatory Disorders
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
- Pregnancy and Medication Impact
- Biosimilars and Bioanalytical Methods
- Chronic Lymphocytic Leukemia Research
- Tuberculosis Research and Epidemiology
- Gastrointestinal disorders and treatments
- Celiac Disease Research and Management
- Vasculitis and related conditions
- Mycobacterium research and diagnosis
- Pharmaceutical studies and practices
- Systemic Lupus Erythematosus Research
- Appendicitis Diagnosis and Management
- Nutrition and Health in Aging
- Adolescent and Pediatric Healthcare
- Clostridium difficile and Clostridium perfringens research
- Biomedical Ethics and Regulation
- Gas Sensing Nanomaterials and Sensors
- Rheumatoid Arthritis Research and Therapies
- Acute Lymphoblastic Leukemia research
Hospital Universitario Araba
2016-2025
Hospital Txagorritxu
2010-2023
University of the Basque Country
2014
This study sought to determine the prevalence of malnutrition in patients with inflammatory bowel disease, analyse dietary beliefs and behaviours these patients, their body composition, evaluate muscular strength identify factors associated patients.This was a prospective, multicentre study. Crohn's disease ulcerative colitis from 30 Spanish centres, outpatient clinics, were included. A questionnaire 11 items applied obtain data patients' behaviour beliefs. Patients who accepted evaluated...
Since the first description of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), infection produced by this microorganism (COVID-19) has been confirmed in 1,469,544 individuals around world (www.healthmap.org/covid-19/). In Spain, case COVID-19 was reported on January 31, 2020, and currently there are 146,690 cases 14,555 deaths secondary to (Ministry Health, Consumer Affairs Social Welfare, April 7, 2020). Basque Country (Spain), 9452 subjects have a positive test for...
Abstract Background Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety ustekinumab in Crohn’s disease (CD) patients real-world clinical practice. Methods A retrospective, multicentre study was conducted Spain with active CD who had received ≥1 intravenous dose for ≥6 months. Primary outcome retention rate; secondary outcomes were identify predictive factors drug retention, short-term remission (week 16), loss response efficacy...
Abstract Background Mesalazine suppositories are recommended in guidelines for the induction and maintenance of remission patients with ulcerative proctitis (UP). Nevertheless, nonadherence can be frequent dose mesalazine treatment remains unknown. The aim this study was to determine frequency non-adherence suppositories, evaluate potential factors impact on quality life number relapses UP. Methods A multicenter, prospective observational designed ≥18 years old UP under (Claversal© 500 mg,...
Abstract Background For children born to mothers with inflammatory bowel disease (IBD), the effects of maternal inflammation and exposure biologic drugs during pregnancy may be significant. Elevated systemic markers are linked adverse birth outcomes impaired infant growth. However, specific evaluation within IBD context remains limited, impact drug on early anthropometric is still uncertain. Aim: analyze development malnutrition risk first year life based intrauterine breastfeeding biologics...
i] To evaluate the evolution of pregnancies and offspring after inflammatory bowel disease [IBD] surgery during pregnancy; ii] to describe indications, surgical techniques, frequency caesarean section concomitant with surgery.Patients operated on due IBD pregnancy 1998 were included. Participating clinicians asked review their databases identify cases. Data patients' demographics, characteristics, medical treatments, activity, outcomes, surgery, delivery, foetal maternal recorded.In all, 44...
Summary Background Ustekinumab is approved for ulcerative colitis (UC). Aims To assess the durability of ustekinumab in patients with UC and its short‐term effectiveness, tolerability clinical practice. Methods Retrospective, multicentre study who had received their first dose at least 16 weeks before inclusion. Patients were followed until treatment discontinuation or last visit. Only active disease start considered effectiveness analysis. stopped visit not to be subsequent remission....
The impact of biologics on the risk postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack evidence more relevant for ustekinumab and vedolizumab.To evaluate PC.A retrospective study was performed 37 centres. Patients treated with within 12 weeks before surgery were considered "exposed". exposure 30-day PC infections assessed by logistic regression propensity score-matched analysis.A total 1535 surgeries 1370 patients. Of them, 711...
Previous data support that the inflammatory process underlying ulcerative colitis (UC) and Crohn's disease (CD) can start years before diagnosis. The aim of this study was to determine if patients with an incidental diagnosis UC or CD demonstrate increase in healthcare utilization preceding symptomatic onset disease.We performed a multicenter, retrospective, hospital-based, case-control study. Patients during colorectal cancer screening program at 9 hospitals were included. Cases matched 1:3...
Real-world data on the effectiveness of upadacitinib for inflammatory bowel disease (IBD) are limited. To assess persistence, effectiveness, and safety in a real-world scenario.
Intra-abdominal abscesses complicating Crohn's disease [CD] are a challenging situation. Their management, during hospitalisation and after resolution, is still unclear. Adult patients with CD complicated intra-abdominal abscess. who required hospitalisation, were included from the prospectively maintained ENEIDA registry GETECCU. Initial strategy effectiveness safety to resolve abscess was assessed. Survival analysis performed evaluate recurrence risk. Predictive factors associated...
Tratamiento con infliximab en paciente enfermedad de Crohn íleo-colónica y arteritis TakayasuPalabras clave: Infliximab
Polycystic liver disease (PLD) is a hereditary inherited by autosomal dominant trait that occurs as frequent extrarenal manifestation of polycystic kidney (ADPKD). We report case 59-year-old woman diagnosed with ADPKD associated PLD. End-stage chronic renal failure secondary Budd-Chiari syndrome developed during the patient’s clinical course. She underwent combined and transplantation, successful response over 9-year follow-up period.
Ustekinumab has shown efficacy in Crohn’s Disease (CD) patients. To identify patient profiles of those who benefit the most from this treatment would help to position drug therapeutic paradigm CD and generate hypotheses for future trials. The objective analysis was determine whether baseline characteristics are predictive remission durability ustekinumab, its positioning with respect prior use biologics a significant effect after correcting disease severity phenotype at using interpretable...
Background: Infliximab seems to be the most efficacious of three available anti-TNF agents for ulcerative colitis (UC) but little is known when it used as second anti-TNF. Objectives: To compare clinical and treatment outcomes a subcutaneous or intravenous in UC patients. Design: Retrospective observational study. Methods: Patients from ENEIDA registry treated consecutively with infliximab (or vice versa), naïve other biological agents, were identified grouped according administration route...
Abstract Background Understanding the impact of in utero exposure to biologic medications children is crucial providing recommendations during pregnancy. The effect biologics, particularly non-anti-TNF ones, on children's psychomotor development, has been inadequately studied. Our aim was evaluate biologics development first year life. Methods Data from born IBD patients included DUMBO registry with complete Age and Stages Questionnaire (AQS-3) available up 12 months age were analysed. a...
Abstract Background Primary aim: To assess the durability of ustekinumab treatment in patients with ulcerative colitis (UC). Secondary aims: short-term effectiveness, response, and tolerability clinical practice. Methods Retrospective, multicenter study including UC who had received 1st dose at least 16 weeks before inclusion. Patients were followed-up from to discontinuation or last visit. Only active disease [Partial Mayo Score (PMS)>2] start considered effectiveness analysis....
Abstract Background Upadacitinib (UPA) has demonstrated its efficacy in patients with inflammatory bowel disease (IBD) clinical trials. However, these results may differ from those achieved practice. Thus, persistence and safety should be analysed a real-world scenario. Main aim: to evaluate the of UPA real life, both Crohn’s (CD) ulcerative colitis (UC). Secondary aims: assess effectiveness UPA. Methods Multicentre, retrospective study IBD who received for Persistence was calculated date...
Crohn's disease (CD) varies by location, potentially affecting therapy efficacy and surgery risk, although research on this topic is conflicting. This study aims to investigate the independent association between CD location therapeutic patterns.
Abstract Purpose Crohn’s disease (CD) is a progressive disorder leading to cumulative bowel damage. The Lémann index validated tool that can help in monitoring the progression of and evaluating effectiveness different therapies. Our aim was describe main radiological findings incidentally diagnosed CD evaluate damage this subgroup compared patients at later stages. Methods Patients with an incidental diagnosis during colorectal cancer screening program were controls cohort after symptomatic...